|Dr. De-Chao Yu Ph.D.||Chairman & CEO||N/A||N/A||1964|
|Dr. Yong Jun Liu M.D., Ph.D.||Pres||N/A||N/A||1969|
|Mr. Hao Xi Ede||CFO & Exec. Director||N/A||N/A||1959|
|Dr. Changshou Gao||Sr. VP & CTO||N/A||N/A||N/A|
|Ms. Vivian Zhang||Chief People Officer||N/A||N/A||N/A|
|Mr. Min Liu||Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Dongming Wang||Sr. VP of Quality||N/A||N/A||N/A|
|Ms. Yanju Wang||Joint Company Sec.||N/A||N/A||1989|
|Ms. Lok Yee Chan A.C.I.S., A.C.S.||Joint Company Sec.||N/A||N/A||1991|
|Ms. Linda M. Pullan||VP of Bus. Devel.||N/A||N/A||N/A|
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-303, an adalimumab biosimilar for autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it develops IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung, esophageal, and gastric cancer, as well as Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib; NeoCura Bio-Medical Technology Co. Ltd. to study the combination therapy of Sintilimab and neoantigen vaccine NEO_PLIN2101 for cancer treatment; and Eli Lilly and Company, and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Innovent Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.